Huluwa Pharmaceutical Group Included in the 2025 China Premium Consumer Brands List, Demonstrating Leadership in Pediatric Pharmaceuticals

Recently, the Ministry of Industry and Information Technology (MIIT) released the 2025 China Premium Consumer Brands list. Huluwa Pharmaceutical Group was selected based on its outstanding product quality, sustained innovation capability, and strong consumer reputation, becoming a representative enterprise of the pharmaceutical industry in the Hainan Free Trade Port.

The China Premium Consumer Brands selection is an important initiative by MIIT to implement the decisions and arrangements of the CPC Central Committee and the State Council on expanding domestic demand and promoting consumption, and to establish a tiered system of China's premium consumer brands. The selection was conducted in strict accordance with the Notice of the General Office of MIIT on Building a Tiered System of China's Premium Consumer Brands. After enterprise application, provincial preliminary review and recommendation, expert evaluation, and extensive consultation with relevant departments and industry associations, the final list was determined. It represents an authoritative recognition of corporate overall strength and market competitiveness. This selection indicates that Huluwa Pharmaceutical Group's performance in multiple dimensions, including product R&D, quality control, and customer service, has received high recognition at both national and industry levels.

As a leading pediatric pharmaceutical enterprise rooted in Hainan, Huluwa Pharmaceutical Group has consistently upheld the mission of "Huluwa, Healthy Chinese Children", focusing on the field of children's health and building a full industrial chain covering drug R&D, manufacturing, and sales. Leveraging the policy advantages of the Hainan Free Trade Port, such as "zero tariffs" and "low tax rates", Huluwa Pharmaceutical Group will fully seize the opportunities brought by the island-wide customs closure operation. Guided by national needs, the direction of the Hainan Free Trade Port, and its own strategic positioning, the Group will promote technological innovation and the transformation of research achievements, and build an innovation source for pediatric pharmaceuticals.

Being included in the China Premium Consumer Brands list is both recognition of Huluwa Pharmaceutical Group's past achievements and encouragement for its future development. Taking this opportunity, the company will continue to uphold its commitment to quality, fulfill its social responsibilities, and continuously enhance its brand influence and market competitiveness, contributing further to the development of China's premium consumer brand system and writing a new chapter in safeguarding the health of Chinese children!